Free tool
FAERS Monitor: Adbry
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761180 or its brand name (Adbry, Tralokinumab). Reports on generic versions are filed under their own applications.
Reports
6,706
Serious
923
14% of reports
Hospitalization
340
Death reported
90
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dermatitis atopic900
- drug ineffective856
- pruritus735
- rash496
- eczema465
- injection site pain432
- dry skin287
- injection site erythema239
- erythema225
- product use in unapproved indication223
- injection site pruritus208
- injection site swelling198
- eye pruritus182
- ocular hyperaemia175
- skin exfoliation167
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 549 |
| 2023 | 1,020 |
| 2024 | 1,641 |
| 2025 | 1,894 |
| 2026 | 1,599 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,453 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitis atopicSignal | 900 | 54.4 | 51.2 | 46,475 |
| eczemaSignal | 465 | 28.1 | 25.7 | 12,054 |
| eye pruritusSignal | 182 | 17.1 | 14.8 | 2,728 |
| ocular hyperaemiaSignal | 175 | 11.6 | 10.0 | 1,683 |
| injection site pruritusSignal | 208 | 9.8 | 8.5 | 1,628 |
| injection site swellingSignal | 198 | 8.1 | 7.1 | 1,231 |
| dry skinSignal | 287 | 6.8 | 6.0 | 1,408 |
| skin exfoliationSignal | 167 | 6.2 | 5.4 | 728 |
| injection site erythemaSignal | 239 | 6.1 | 5.3 | 1,007 |
| pruritusSignal | 735 | 6.0 | 5.6 | 3,114 |
| injection site painSignal | 432 | 4.4 | 4.0 | 1,156 |
| rashSignal | 496 | 3.6 | 3.3 | 934 |
| erythemaSignal | 225 | 3.4 | 3.0 | 389 |
| product use in unapproved indicationSignal | 223 | 2.8 | 2.5 | 264 |
| drug ineffectiveSignal | 856 | 2.0 | 1.9 | 481 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.